Echo IQ (ASX:EIQ) partnered with the Mayo Clinic Platform to advance the clinical validation study of its cloud-based heart failure decision support platform, EchoSolv HF, according to a Thursday filing with the Australian bourse.
The study, set to begin this quarter, will evaluate the model's ability to detect various forms of heart failure and is key towards securing FDA clearance for EchoSolv HF, anticipated in the second half of the year, the filing said.
Shares of the company rose 2% on market close.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.